Crystal polymorphism of inclusion compound and method for producing same, and curable resin composition

Patent metadata

Field	Value
Publication number	US-10266642-B2
Application number	US-201515504112-A
Country	US
Kind code	B2
Filing date	Aug 27, 2015
Priority date	Sep 8, 2014
Publication date	Apr 23, 2019
Grant date	Apr 23, 2019

Abstract

It is to provide a more stable crystal polymorph of a clathrate compound consisting of 1,1,2,2-tetrakis(4-hydroxyphenyl)ethane and 2-phenyl-4-methyl-5-hydroxymethylimidazole (molar ratio 1:2). A novel crystal polymorph of a clathrate compound, consisting of 1,1,2,2-tetrakis(4-hydroxyphenyl)ethane and 2-phenyl-4-methyl-5-hydroxymethylimidazole (molar ratio 1:2) and has diffraction peaks at diffraction angles (2θ) of 11.20°, 13.36°, 14.36°, 18.16°, 19.20°, 19.68°, 20.84°, 21.48°, 22.56°, 23.76° and 24.08° in a powder X-ray diffraction pattern as measured using a CuKα ray, can be obtained by, for example, further recrystallizing a crystal obtained by a conventionally known method or the like.

First claim

The invention claimed is:

1. A crystal polymorph of a clathrate compound consisting of 1,1,2,2-tetrakis(4-hydroxyphenyl)ethane and 2-phenyl-4-methyl-5-hydroxymethylimidazole, wherein:
a molar ratio of 1,1,2,2-tetrakis(4-hydroxyphenyl)ethane to 2-phenyl-4-methyl-5-hydroxymethylimidazole is 1:2, and
the crystal polymorph has diffraction peaks at diffraction angles (2θ) of 11.20°, 13.36°, 14.36°, 18.16°, 19.20°, 19.68°, 20.84°, 21.48°, 22.56°, 23.76%, and 24.08° in a powder X-ray diffraction pattern as measured using a CuKα ray.

2. A method of producing the crystal polymorph according to claim 1 , comprising a step of recrystallizing a crystal of a clathrate compound consisting of 1,1,2,2-tetrakis(4-hydroxyphenyl)ethane and 2-phenyl-4-methyl-5-hydroxymethylimidazole, wherein the crystal has diffraction peaks at diffraction angles (2θ) of 8.12°, 10.12°, 12.72°, 13.68°, 14.60° and 20.24° in a powder X-ray diffraction pattern as measured using a CuKα ray.

3. A method of producing the crystal polymorph according to claim 1 , comprising a step of crystallizing a clathrate compound consisting of 1,1,2,2-tetrakis(4-hydroxyphenyl)ethane and 2-phenyl-4-methyl-5-hydroxymethylimidazole from an alcohol solution or suspension containing 1,1,2,2-tetrakis(4-hydroxyphenyl)ethane and 2-phenyl-4-methyl-5-hydroxymethylimidazole.

4. A curing agent for epoxy resins or a curing accelerator for epoxy resins, containing the crystal polymorph according to claim 1 .

5. A curable resin composition containing an epoxy resin and the curing agent for epoxy resins or the curing accelerator for epoxy resins according to claim 4 , or a cured product thereof.

Assignees

• Nippon Soda Co

Inventors

• Ono Kazuo

Classifications

• C08G59/56

  together with other curing agents · CPC title

• C08G59/40

  characterised by the curing agents used · CPC title

• C07C37/84

  by crystallisation · CPC title

• C07D233/64

  with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine · CPC title

• C08G59/621 Primary

  Phenols · CPC title